Chinese drug regulation proposals spell big changes for industry
This article was originally published in SRA
Executive Summary
The China Food and Drug Administration has proposed amendments to the Drug Registration Regulation (DRR) that could introduce significant changes for pharmaceutical companies operating in China1,2.